Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etuvetidigene Autotemcel→

Etuvetidigene Autotemcel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Autologous CD34+ haematopoietic stem-cell gene therapylentiviral WAS gene addition product
Mechanism of action
Autologous CD34+ cells are transduced ex vivo with a lentiviral vector carrying functional WAS complementary DNA. Reinfused gene-modified stem cells engraft and generate haematopoietic progeny expressing WAS protein, addressing the underlying Wiskott-Aldrich syndrome gene defect.
Indications / reported uses
  • Treatment of paediatric patients aged 6 months and older and adults with Wiskott-Aldrich syndrome caused by a WAS gene mutation, for whom HSCT is appropriate and no suitable HLA-matched related donor is available

Sources: US FDA — WASKYRA product information · US FDA Purple Book — WASKYRA · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Autologous CD34+ haematopoietic stem-cell gene therapy; lentiviral WAS gene addition product

Mechanism of action

Autologous CD34+ cells are transduced ex vivo with a lentiviral vector carrying functional WAS complementary DNA. Reinfused gene-modified stem cells engraft and generate haematopoietic progeny expressing WAS protein, addressing the underlying Wiskott-Aldrich syndrome gene defect.

General use cases

  • Treatment of paediatric patients aged 6 months and older and adults with Wiskott-Aldrich syndrome caused by a WAS gene mutation, for whom HSCT is appropriate and no suitable HLA-matched related donor is available

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Etuvetidigene Autotemcel Environmental Risk Assessment (ERA) (the Etuvetidigene Autotemcel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.